Iqra Muzammil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iqra Muzammil has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Amjad Islam Aqib
Department of Medicine, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan
1 shared publication Aqsa Ahmad
1 shared publicationArslan Rasool
1 shared publicationImran Khan Sohrani
1 shared publication- Mudassir Ali
Department of Diabetes and Endocrinology University Hospital North Tees and Hartlepool, NHS Foundation Trust, TS 19 8PE, UK
1 shared publication Muhammad Aamir Naseer
1 shared publication
Latest Publications
- 10 May 2023
- Published by Wiley in Zoonoses and Public Health
- Vol. 70 (5) , 420-433
Molecular characterization of vancomycin‐resistant Staphylococcus aureus isolated from bovine milk
Vancomycin‐resistant Staphylococcus aureus (VRSA) is a zoonotic life‐threatening pathogen. Vancomycin exhibits anti‐bacterial activity by inhibiting peptidoglycan synthesis by binding to the D‐ala‐D‐ala terminus of the peptidoglycan. But in VRSA, D‐ala‐D‐ala is replaced by D‐ala‐D‐lactate due to the presence of vanA, vanB or vanD genes. This study was intended to identify the molecular prevalence of VRSA in 768 bovine milk samples, risk factor association, antibiogram profile and bioinformatics analysis of VRSA by targeting vanB gene. Out of a total of 248 S. aureus isolates from mastitic milk samples, the phenotypic and genotypic prevalence of VRSA was estimated to be 17.74% and 10.89%, respectively. Farm‐level risk factors including use of improper milking technique, lack of milker's care during milking, unhygienic conditions during milking and no dry cow therapy were found to be significantly associated (p < 0.05). Anti‐microbial susceptibility testing of VRSA isolates exhibited the highest resistance to oxytetracycline, followed by oxacillin and Trimethoprim+sulfamethoxazole. The current study sequences showed more resemblance with reported sequences from Iraq (MN747834) and Egypt (MK095504, MK087830), which belong to vanB gene from S. aureus as compared to sequences from other countries, which belong to vanB gene from the genus Enterococcus. The Genetic Algorithm for Recombination Detection (GARD) found 234 potential breakpoints, translating into a search room of 123,883,305 models with up to 4 breakpoints. The phylogenetic motif profiling method discovered evolutionarily conserved residues across target genes' homologous protein sequences. These residues were discovered to be conserved in drug‐resistant target proteins over the evolutionary process and may play a key role in their function. The current study revealed a molecular prevalence of VRSA in dairy animals, along with molecular analysis of vancomycin resistance in S. aureus by targeting the vanB gene using standard bioinformatics tools. The occurrence of VRSA in animals requires serious attention because this pathogen has zoonotic potential, so it can become a greater risk to consumer health.
- 10 May 2023
- Published by Wiley in Zoonoses and Public Health
- Vol. 70 (5) , 420-433
Molecular characterization of vancomycin‐resistant Staphylococcus aureus isolated from bovine milk
Vancomycin‐resistant Staphylococcus aureus (VRSA) is a zoonotic life‐threatening pathogen. Vancomycin exhibits anti‐bacterial activity by inhibiting peptidoglycan synthesis by binding to the D‐ala‐D‐ala terminus of the peptidoglycan. But in VRSA, D‐ala‐D‐ala is replaced by D‐ala‐D‐lactate due to the presence of vanA, vanB or vanD genes. This study was intended to identify the molecular prevalence of VRSA in 768 bovine milk samples, risk factor association, antibiogram profile and bioinformatics analysis of VRSA by targeting vanB gene. Out of a total of 248 S. aureus isolates from mastitic milk samples, the phenotypic and genotypic prevalence of VRSA was estimated to be 17.74% and 10.89%, respectively. Farm‐level risk factors including use of improper milking technique, lack of milker's care during milking, unhygienic conditions during milking and no dry cow therapy were found to be significantly associated (p < 0.05). Anti‐microbial susceptibility testing of VRSA isolates exhibited the highest resistance to oxytetracycline, followed by oxacillin and Trimethoprim+sulfamethoxazole. The current study sequences showed more resemblance with reported sequences from Iraq (MN747834) and Egypt (MK095504, MK087830), which belong to vanB gene from S. aureus as compared to sequences from other countries, which belong to vanB gene from the genus Enterococcus. The Genetic Algorithm for Recombination Detection (GARD) found 234 potential breakpoints, translating into a search room of 123,883,305 models with up to 4 breakpoints. The phylogenetic motif profiling method discovered evolutionarily conserved residues across target genes' homologous protein sequences. These residues were discovered to be conserved in drug‐resistant target proteins over the evolutionary process and may play a key role in their function. The current study revealed a molecular prevalence of VRSA in dairy animals, along with molecular analysis of vancomycin resistance in S. aureus by targeting the vanB gene using standard bioinformatics tools. The occurrence of VRSA in animals requires serious attention because this pathogen has zoonotic potential, so it can become a greater risk to consumer health.
- 5 January 2022
- Published by Taylor & Francis
- p. 205-228
Metallic and Non-metallic Nanoparticles against Viruses
Viral diseases pose a public health concern and are one of the leading causes of deaths worldwide. Additionally, repeated administrations and high doses of antivirals result in severe side effects and antiviral resistance. There is a dire need to develop alternative strategies to combat this challenge with maximum human benefit. Nanoparticles (NPs) possess distinctive properties that provide a novel platform for the development of potential and effective agents by modifying the materials at the nano level with remarkable physicochemical properties, a high ration of surface area to volume, and increased reactivity. Metallic nanoparticles have applications in various fields like cosmetics, coatings, biotechnology, electronics, and packaging. Among metallic nanoparticles, silver nanoparticles (AgNPs) have antiviral, antibacterial, and antifungal properties to enhance the host immunity against pathogens. Integration of classic antiviral agents, in the form of multiple ligands, with nanostructures proves adventitious by creating a high local concentration of active molecules. However, only a few efforts have been made in nanotechnology-based drug delivery area. Future challenges of nano formulations for antiviral drugs are safety/toxicity, high drug payloads, upscaled production, smart nanocarriers, sustained release, and targeting. A number of problems are still left that need to be addressed for successful implementation of nano-preparations in clinics. This chapter will cover biocidal effects of metallic and nonmetallic nanoparticles against viruses, their mechanisms of action, nanotherapeutic agents of clinical importance, and challenges in nanotherapeutics.
- 5 January 2022
- Published by Taylor & Francis
- p. 205-228
Metallic and Non-metallic Nanoparticles against Viruses
Viral diseases pose a public health concern and are one of the leading causes of deaths worldwide. Additionally, repeated administrations and high doses of antivirals result in severe side effects and antiviral resistance. There is a dire need to develop alternative strategies to combat this challenge with maximum human benefit. Nanoparticles (NPs) possess distinctive properties that provide a novel platform for the development of potential and effective agents by modifying the materials at the nano level with remarkable physicochemical properties, a high ration of surface area to volume, and increased reactivity. Metallic nanoparticles have applications in various fields like cosmetics, coatings, biotechnology, electronics, and packaging. Among metallic nanoparticles, silver nanoparticles (AgNPs) have antiviral, antibacterial, and antifungal properties to enhance the host immunity against pathogens. Integration of classic antiviral agents, in the form of multiple ligands, with nanostructures proves adventitious by creating a high local concentration of active molecules. However, only a few efforts have been made in nanotechnology-based drug delivery area. Future challenges of nano formulations for antiviral drugs are safety/toxicity, high drug payloads, upscaled production, smart nanocarriers, sustained release, and targeting. A number of problems are still left that need to be addressed for successful implementation of nano-preparations in clinics. This chapter will cover biocidal effects of metallic and nonmetallic nanoparticles against viruses, their mechanisms of action, nanotherapeutic agents of clinical importance, and challenges in nanotherapeutics.